The market research report on the coronary stent market covers market sizing and forecast, market share, industry trends, growth drivers, and vendor analysis. The market study includes insights on segmentation by product (drug-eluting stents, bare metal stents, and bioresorbable stents), design (permanent, fully degradable), end-users (hospitals, specialty cardiology centers, ambulatory surgical centers), and geography (North America, Europe, APAC, Latin America, and MEA).
Coronary Stent Market: Overview
CAD is a major cause of heart-related morbidities and accounts for 20-25% deaths globally.
The growing prevalence of cardiovascular diseases (CVD), especially vascular diseases, has been a major growth driver for the coronary stent market. Over the years, coronary stents have witnessed several technological enhancements, particularly design innovations. Stent manufacturers are focusing primarily on R&D activities and commercialization of innovative drug-eluting stent (DES) systems due to the high prevalence of coronary artery diseases.
Several government agencies and vendors are spreading awareness and information about the availability of the latest-generation heart stents and their advantage over conventional invasive procedures. The emergence of bioresorbable vascular scaffolds, the high growth potential of third generation DESs with low strut thickness, and new product approvals and launches are some of the primary factors accelerating growth of the coronary stent market. Many surgeons are implanting DESs with low strut thickness for treating CAD. This is expected to increase the commercialization of a diverse range of DESs with low strut thickness, thereby positively contributing to the growth of the coronary stent market globally.
Further, new product approvals are contributing majorly toward the growth of the market and are likely to have a significant impact on the adoption of coronary stents in the coming years. Abbott, B. Braun Melsungen, Boston Scientific, Biosensors International GroupMedtronic, BIOTRONIK, Microport Scientific, and Terumo have launched a diverse range of drug-eluting stents in recent years, which are expected to augur well for the growth of the coronary stent market. The coronary stents market is likely to reach more than $11 billion by 2024, growing at a CAGR of around 7% during 2018–2024.
The market research report includes a detailed segmentation of the market by product, design, end-users, and geography.
Coronary Stent Market: Product
Bioresorbable stents are likely to witness rapid growth during the forecast period
The high prevalence/incidence of CVDs is a major driver for the growth of drug-eluting stents. The high incidence of coronary artery disease(CAD), coupled with the increasing elderly population, is a significant factor driving the demand for drug-eluting stents.
Bare metal stents are growing at a steady rate. High CAD occurrences, technological advancements, and a steady increase in demand in emerging economies are factors responsible for growth bare metal stents. Further, the demand for bare metal stents is likely to grow primarily from price-sensitive markets such as developing and low-income countries, where the uptake of PCI procedures has steadily increased over the past few years.
Bioresorbable stents are growing at a faster pace and are likely to witness rapid growth during the forecast period. With the availability of a few commercial and promising investigational devices, bioresorbable stents are likely to offer tremendous growth opportunities for vendors in coming years.
Coronary Stent Market: Design
High incidences of CAD have become a major driver for fully degradable stents
The permanent coronary stents segment is growing significantly and captured more than half of the market in 2018. Permanent heart stents are non-degradable devices made up from metal alloys such as stainless steel, cobalt chromium, and platinum chromium. They are gaining prominence in the market due to their safety and efficacy.
Fully degradable heart stents are growing at a stable rate. The rise in CVDs, especially vascular diseases, has become a major growth driver for innovative fully degradable types. Further, the heart stent manufacturers are focusing on R&D activities and commercialization of innovative products such as BRSs.Several emerging and major players are actively engaged in the development and commercialization of BRSs due to their huge market potential. For instance, Abbott is developing Absorb, second-generation BRS, and is actively conducting clinical trials to gain regulatory approvals.
Coronary Stent Market: End-user
Specialty cardiology centers are growing at a steady rate due to the presence of sophisticated infrastructure for the treatment of CVDs
Hospitals are the largest end-users of coronary stents. The growing aging population, changing lifestyle patterns, and the increasing prevalence of CVDs are fueling market growth. Further, a significant number of patients prefer to undergo surgeries in hospitals due to better reimbursement policies. The availability of reimbursement in hospitals is a major driver for the high volume of PCI procedures in the healthcare sector.The demand for highly advanced and innovative PCI procedures like robot-assisted techniques are being performed to implant a diverse array of drug eluting, bare metal, and bioabsorbable stents.
Specialty cardiology centers and interventional cardiology training are growing at a steady rate due to the presence of sophisticated infrastructure related to the diagnosis and treatment of CVDs. Significant advances in surgical procedures and the high demand for CVD care have also contributed to the growth of the segment. ASCs are outpatient surgery centers that provide advanced healthcare facilities to patients. These centers are cost-effective and offer quality care with the minimal indirect cost of treatment. Cohesively, these factors are expected to drive the coronary stent market during the forecast market.
Coronary Stent Market: Geography
High penetration and acceptance of stent-based PCI procedures has supported North America’s dominance in the market
North America captured half of the global coronary stent market in 2018. The presence of a large pool of patient population with CAD requiring coronary stents, a high acceptance of advanced and innovative heart stents, and high awareness toward stent-based PCI procedures have collectively supported North America’s dominance in the market.
Germany, the UK, France, Italy, and Spain are the major revenue contributors in the coronary stent market in Europe. The presence of highly sophisticated healthcare infrastructure, high awareness regarding advantages of PCI procedures, and increased R&D investments on innovative coronary stents are major driver driving the Europe coronary stent market.
APAC is likely to offer lucrative opportunities for a diverse range of coronary stents. Favorable government initiatives and the growing medical tourism industry in APAC are expected to drive the coronary stent market in the region during the forecast period.
Latin America and MEA accounted small shares in 2018. Brazil and Mexico are the major revenue contributors in the Latin America market, whereas, Turkey, Saudi Arabia, South Africa, Israel, and a few Gulf countries are major revenue contributors in the MEA region.
Key Countries Profiled
Key Vendor Analysis
The coronary stent market is highly dynamic due to the presence of several global, regional, and local players offering a broad range of stents. Vendors, especially global players, are increasingly focusing on pursuing inorganic growth strategies such as acquisitions and investments in startup and emerging companies to expand their presence, enhance product portfolio, and improve expertise in the market. Leading players are focusing on implementing strategies such as product approvals, expanded indication approvals, conducting clinical trials, marketing, and promotional activities, acquisitions, increase R&D investment, and strengthen their distribution networks to enhance their market share and presence in the coronary stent market.
Other prominent vendors are Arterial Remodeling Technologies, Alvimedica, Balton, Cardionovum, CelonovaBioSciences, Comed, Cordis, Elixir Medical, Endocor, Eucatech, Eurocor Tech, Hexacath, InSitu Technologies, Innovative Healthcare Technologies, Lepu Medical Technology (Beijing), Medinol, Meril Life Sciences, Micell Technologies, MicroPort Scientific, Minvasys, OrbuSneich Medical, Q3 Medical Devices, REVA Medical, Rontis, S3V Vascular Technologies, Sahajanand Medical Technologies, Scitech, Stentys, Svelte Medical, Translumina Therapeutics, USM Healthcare, Vascular Concepts, and Wellinq.
Key Market Insights
Get the updated report free if published within 100 days of purchase
Free datasheet worth $1500 with team and corporate license.
10% free customization. Speak to our analyst